Examples of 'b-raf' in a sentence
Meaning of "b-raf"
B-raf is a noun referring to a mutated gene that plays a role in various cancers
How to use "b-raf" in a sentence
Basic
Advanced
b-raf
Diagnostic test for susceptibility to B-Raf kinase inhibitors.
The mutant B-Raf can be detected by a variety of immunoassay methods.
Abnormal mutations in the body have been found only in B-Raf.
Small molecule inhibitors of B-Raf are being developed for anticancer therapy.
Often these methods employ an antibody specific to mutant B-Raf.
In particular, B-Raf mutations have been detected in a large percentage of malignant melanomas.
Compounds of the invention are tested for their ability to inhibit the activity of b-Raf.
The neuroprotective properties of B-Raf inhibitors may be determined by the following in vitro assay,.
Suitably, the pharmaceutically active compounds of the invention are used in combination with a B-Raf inhibitor.
This gene encodes a protein called B-Raf which is involved in directing cell growth.
Metastatic melanomas and thyroid tumours which overexpress the mutated form of the B-Raf protein ;.
Resistance to B-raf inhibition may be characterized by numerous phenomena.
The levels of phosphorylated MEK are elevated due to the mutation of B-Raf.
B-Raf mutations have been detected in a large percentage of malignant melanomas.
The role of Raf proteins like B-Raf is indicated in the center.
See also
B-Raf is one of the most frequently mutated genes in human cancers.
Most of the mutants stimulate enhanced B-Raf kinase activity toward MEK.
B-Raf is a member of the Raf kinase family of growth signal transduction protein kinases.
In some embodiments, the patient was not previously treated with B-raf antagonist.
Hyperkeratosis can also be caused by B-Raf inhibitor drugs such as Vemurafenib and Dabrafenib.
In some embodiments, the individual has previously been treated with a B-raf antagonist.
B-Raf inhibitors can also be used in conjunction with other cancer therapies . Kits.
In some disclosures, the individual has not been previously treated with a B-raf antagonist.
Among these, B-Raf plays a key role in connecting the signal transduction from Ras to MEK.
Among the three isoforms, studies have shown that B-Raf functions as the primary MEK activator.
Asterisks denote residues conserved between EGFR and B-Raf.
Mutation in b-raf and n-ras are often found in patients with this disease.
Combination comprising an MEK inhibitor and a B-raf inhibitor.
C-raf and b-raf are preferred targets for compounds of the present invention.
In embodiments, the tyrosine kinase inhibitor is a B-Raf enzyme inhibitor.
In contrast, mutant B-Raf has been reported to be constantly active, disrupting the signaling relay.
A number of kinase inhibitors are known, including those that inhibit B-Raf.
In some embodiments, mutant B-raf is constitutively active.
BRAF " is a human gene that makes a protein called B-Raf.
Examples of small molecule inhibitors of B-Raf include but are not limited to dabrafenib ( Tafinlar ® ).
In some embodiments, the patient 's cancer has been shown to express a B-raf biomarker.
B-Raf and A-Raf are highly expressed in neural tissue and urogenital tissue, respectively.
Activation of a downstream element in the Ras pathway includes, for example, mutation within B-Raf.
Among these, B-Raf plays a key role in connecting the signaling from Ras to MEK.
For example, the disease can be a melanoma that is resistant to a B-Raf and / or MEK inhibitor.
B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms.
Other kinases used in the kinase selectivity experiments were, for example, b-Raf and KDR.
Resistance to B-raf inhibition may refer to B-raf activity in the presence of a B-raf antagonist.
Typically, the disorder is a cancer such that inhibition of MEK and / or B-Raf has a beneficial effect.
In the context of this invention, a " B-Raf kinase inhibitor " inhibits activity of a B-Raf kinase.
Fig . 22 shows the melting results of a blind study of the B-raf mutation.
K-ras and B-raf mutations and anti-EGFr antibody therapy.
Indeed, vemurafenib and dabrafenib target only melanomas mutated on B-Raf ( approximately 50 % of the metastatic melanomas ).
Typically, B-raf mutations observed in cancer include activating mutations, such as the V600E mutation.
Figures 6A-6C, Sequence alignment of selected regions within the EGFR and B-Raf kinase domains.
